TechNavio Announces the Publication of its Research Report – Global Nanotechnology Drug Delivery Market 2012-2016

Renewable energy

TechNavio today launched its report Global Nanotechnology Drug Delivery Market 2012-2016 based on an in-depth analysis covering the Americas, and the EMEA and APAC regions. The report aims to aid decision makers’ understanding of the present and future landscape of the market.
Commenting on the report, an analyst from TechNavio’s Healthcare team said: ”Pharmaceutical and biotechnology companies are focusing on capitalizing on the potential of nanotechnology-enabled drug delivery. Nanotechnology-enabled drug delivery systems are helping pharmaceutical and biotechnology companies to counter the threat of generics. Reformulation helps in extending the product life cycle, and novel reformulations help an existing drug candidate to qualify as a new chemical entity. This increases profitability and discourages competition during the drug’s most profitable years.”
According to the report, increasing government funding is one of the major drivers in the Global Nanotechnology Drug Delivery market. Government programs in various countries such as the US, the UK, Germany, and China exist for funding various R&D initiatives in nanotechnology, which is boosting the growth of the market.
Further, the report states that various manufacturing issues constitute one of the major challenges in the Global Nanotechnology Drug Delivery Market.
The report also includes a discussion of the key vendors operating in this market. The key vendors dominating this market space are Celgene Corp., GlaxoSmithKline plc, IOTA NanoSolutions Ltd., Lena Nanoceutics Ltd., and SkyePharma plc. The other vendors mentioned in the report are Merck & Co. Inc., Pfizer Inc., AlphaRx Inc., Amgen Inc., Angiotech Pharmaceuticals Inc., Biophan Technologies Inc., Calando Pharmaceuticals Inc., Cephalon Inc., Cerulean Pharma Inc., Copernicus Therapeutics Inc., CritiTech Inc., CytImmune Sciences Inc., Elan Corp. plc, Debiotech SA, F. Hoffmann-La Roche Ltd., Nano Interface Technology Inc., Spherics Inc., Spectrum Pharmaceuticals Inc., SoluBest Ltd., Sigma-Tau Pharmaceuticals Inc., PharmaNova Inc., Particle Sciences Inc., Novavax Inc., Nanotherapeutics Inc., NanoSight Ltd., NanoCarrier Co. Ltd., NanoBioMagnetics Inc., Nano Interface Technology Inc., Merck Sharp and Dohme Corp., Kuecept Ltd., and Izon Science Ltd.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. For further information on this report, please visit https://www.technavio.com/content/global-nanotechnology-drug-delivery-mar
TechNavio, the market research platform of Infiniti Research Ltd., publishes periodic market research reports on niche and emerging technologies. For more information on our Healthcare market research, please visit https://www.technavio.com/healthcare
Follow us on Twitter @ Technavio

https://www.technavio.com/